Abstract:Context: Visceral pain is a leading symptom for patients with irritable bowel syndrome (IBS) that affects 10% - 20 % of the world population. Conventional pharmacological treatments to manage IBS-related visceral pain is unsatisfactory. Recently, medications have emerged to treat IBS patients by targeting the gastrointestinal (GI) tract and peripheral nerves to alleviate visceral pain while avoiding adverse effects on the central nervous system (CNS). Several investigational drugs for IBS also target the periphery with minimal CNS effects. Evidence of acquisition: In this paper, reputable internet databases from 1960 - 2016 were searched including Pubmed and ClinicalTrials.org, and 97 original articles analyzed. Search was performed based on the following keywords and combinations: irritable bowel syndrome, clinical trial, pain, visceral pain, narcotics, opioid, chloride channel, neuropathy, primary afferent, intestine, microbiota, gut barrier, inflammation, diarrhea, constipation, serotonin, visceral hypersensitivity, nociceptor, sensitization, hyperalgesia. Results: Certain conventional pain managing drugs do not effectively improve IBS symptoms, including NSAIDs, acetaminophen, aspirin, and various narcotics. Anxiolytic and antidepressant drugs (Benzodiazepines, TCAs, SSRI and SNRI) can attenuate pain in IBS patients with relevant comorbidities. Clonidine, gabapentin and pregabalin can moderately improve IBS symptoms. Lubiprostone relieves constipation predominant IBS (IBS-C) while loperamide improves diarrhea predominant IBS (IBS-D). Alosetron, granisetron and ondansetron can generally treat pain in IBS-D patients, of which alosetron needs to be used with caution due to cardiovascular toxicity. The optimal drugs for managing pain in IBS-D and IBS-C appear to be eluxadoline and linaclotide, respectively, both of which target peripheral GI tract. Conclusions: Conventional pain managing drugs are in general not suitable for treating IBS pain. Medications that target the GI tract and peripheral nerves have better therapeutic profiles by limiting adverse CNS effects.

New drugs in the management of the irritable bowel syndrome

New developments in the treatment of irritable bowel syndrome

Irritable bowel syndrome: recent and novel therapeutic approaches

Current and novel therapeutic options for irritable bowel syndrome management

[The proven and the new in the pharmacotherapy of irritable bowel syndrome]

New and Investigational Agents for Irritable Bowel Syndrome

Diagnostic and therapeutic strategies in the irritable bowel syndrome

Pharmacological treatment of irritable bowel syndrome--from concept to sales

Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview

Current state of the non‐pharmacological management of irritable bowel syndrome: an up‐to‐date review of the literature

Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea

Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article

Pharmacological management of irritable bowel syndrome

[Irritable bowel syndrome: current treatment options]

Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M)

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

Current Recommendations and Evidence

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs

Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches

Irritable bowel syndrome: diagnosis and management

The Irritable Bowel Syndrome: Mechanisms and a Practical Approach to Management